Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.

56 demonstrated a positive effect of blinatumomab followed by alloHSCT on OS and the recent RIALTO trial 50 showed a trend toward better RFS and OS in patients treated with blinatumomab followed by alloHSCT. 50 , 56 Results of the recently published randomized phase III study by Locatelli et al. , 52 , 55 where alloHSCT was prospectively indicated in patients with high-risk first-relapse B-cell ALL following a third consolidation course with one cycle of blinatumomab, demonstrated a significant improvement in EFS and OS than in patients treated with chemotherapy.

also in 53,322 other papers